FDA Approves Bkemv, A Potentially Game-Changing Treatment for Rare Blood Diseases
WASHINGTON, D.C. — In a significant advancement for patients with rare blood diseases, the U.S. Food and Drug Administration (FDA) has given its nod to Bkemv (eculizumab-aeeb), the first interchangeable …
FDA Approves Bkemv, A Potentially Game-Changing Treatment for Rare Blood Diseases Read More